SCHEMBL13804239

SCHEMBL13804239

CN(C)CCOC(=O)c1cccc(C(C)(C)C)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PHLPP2 Q6ZVD8 1/20 0.52
▸ ACHE P22303 4/20 0.50
▸ LMNA P02545 2/20 0.49
▸ TSHR P16473 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ CA1 P00915 2/20 0.47
▸ CA2 P00918 2/20 0.47
▸ POLB P06746 1/20 0.44
▸ RAD52 P43351 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ MAOA P21397 1/20 0.44
▸ CNR1 P21554 1/20 0.44
▸ DRD4 P21917 1/20 0.44
▸ HRH2 P25021 1/20 0.44
▸ HTR2A P28223 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23139606 0.92 GAA (0.55) PHLPP2ACHELMNATSHRALDH1A1
SCHEMBL13286763 0.88 ACHE (0.58) ACHELMNATSHRALDH1A1SMN1; SMN2
SCHEMBL11290956 0.82 PHLPP2 (0.67) PHLPP2ACHELMNATSHRALDH1A1
SCHEMBL19185416 0.81 ADRB2 (0.52) ACHEALDH1A1SMN1; SMN2CYP1A2
SCHEMBL13804234 0.81 ACHE (0.51) ACHELMNAALDH1A1
SCHEMBL8636005 0.81 PHLPP2 (0.56) PHLPP2ACHELMNATSHRALDH1A1
SCHEMBL13814475 0.81 PHLPP2 (0.56) PHLPP2LMNATSHRALDH1A1MAPT
SCHEMBL20280575 0.81 PHLPP2 (0.54) PHLPP2ACHELMNATSHRALDH1A1
SCHEMBL1787779 0.80 ACHE (0.57) ACHETSHRALDH1A1KDM4ESMN1; SMN2
SCHEMBL19563523 0.79 PHLPP2 (0.55) PHLPP2ACHELMNATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10947259-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2021-03-16 — — US disclosed
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 — — US disclosed
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 — — US disclosed
US-9522145-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-20 — — US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 — — US disclosed
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2015-07-09 — — US disclosed
US-9012473-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-04-21 — — US disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 — — US disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 — — US disclosed
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-07-24 — — US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 — — US disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2009-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH PHLPP2 2687/4885ACHE 2556/4885LMNA 911/4885
US-20150190390-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 PHLPP2 1721/4885ACHE 4642/4885LMNA 3795/4885
US-10947259-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS PHLPP2 1761/4885ACHE 3695/4885LMNA 3781/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 PHLPP2 2143/4885ACHE 3800/4885LMNA 2164/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH PHLPP2 2687/4885ACHE 2556/4885LMNA 911/4885
US-20090143381-A1 MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS CFTR, ABCB1, ABCC2 PHLPP2 1636/4885ACHE 4639/4885LMNA 3826/4885
US-20140206689-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 PHLPP2 1666/4885ACHE 4616/4885LMNA 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback